公开(公告)号：WO2014086604A1

公开(公告)日：2014-06-12

申请号：PCT/EP2013/074567

申请日：2013-11-25

Applicant: NESTEC S.A.

Inventor： MARTIN, François-Pierre ,  BOULANGE, Claire L. ,  MONTOLIU ROURA, Ivan ,  COLLINO, Sebastiano ,  DUMAS, Marc-Emmanuel ,  HOLMES, Elaine ,  REZZI, Serge André Dominique ,  NICHOLSON, Jeremy ,  KOCHHAR, Sunil

IPC: G01N33/50

CPC classification number: G01N33/50 ,  A61B5/4872 ,  G01N2800/044 ,  G01N2800/50

Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a nnethod that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be trimethylamine-N-oxide.

Abstract translation: 本发明一般涉及营养和健康领域。 特别地，本发明涉及一种新的生物标志物，其用途和方法，其允许其诊断抵抗饮食诱导的体重增加的可能性，和/或易于饮食诱导的体重增加。 例如，生物标志物可以是三甲胺-N-氧化物。

公开(公告)号：WO2013139582A1

公开(公告)日：2013-09-26

申请号：PCT/EP2013/054332

申请日：2013-03-05

Applicant: NESTEC S.A.

Inventor： COLLINO, Sebastiano ,  MONTOLIU ROURA, Ivan ,  MARTIN, François-Pierre ,  GUY, Philippe Alexandre ,  REZZI, Serge André Dominique

IPC: G01N33/68 ,  G01N33/92

CPC classification number: G01N33/49 ,  G01N33/492 ,  G01N33/493 ,  G01N33/6848 ,  G01N33/6893 ,  G01N33/92 ,  G01N2405/06 ,  G01N2570/00 ,  G01N2800/04 ,  G01N2800/50 ,  G01N2800/7042 ,  G01N2800/7095 ,  G09B19/00 ,  G09B19/0092

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using PC-O 40:1 as biomarker.

Abstract translation: 使用基于NMR / MS的代谢组学和靶向脂质组学方法，发明人已经探索了老年人和年轻成年人的老龄化和长寿的代谢表型。 本发明人已经鉴定出降低发展与衰老有关的慢性炎症性疾病的风险的生物标志物，并且提出了一种诊断生活方式的方法，该方法允许使用PC-O 40：1作为生物标志物延迟和/或避免与衰老有关的慢性炎症性疾病。

公开(公告)号：WO2014154492A1

公开(公告)日：2014-10-02

申请号：PCT/EP2014/054909

申请日：2014-03-13

Applicant: NESTEC S.A.

Inventor： MARTIN, François-Pierre ,  COLLINO, Sebastiano ,  MONTOLIU ROURA, Ivan

IPC: G01N33/68

CPC classification number: G01N33/493 ,  A61K31/702 ,  A61K31/733 ,  G01N33/6893 ,  G01N2800/044 ,  G01N2800/52

Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to trimethylamine as a biomarker in urine of the efficacy of prebiotics for the prevention of diet induced weight gain.

Abstract translation: 本发明一般涉及营养和健康领域。 特别地，本发明涉及三氨基胺作为尿中生物标志物的益生元的功效，用于预防饮食诱导的体重增加。

公开(公告)号：WO2014086605A1

公开(公告)日：2014-06-12

申请号：PCT/EP2013/074570

申请日：2013-11-25

Applicant: NESTEC S.A.

Inventor： MARTIN, François-Pierre ,  BOULANGE, Claire L. ,  MONTOLIU ROURA, Ivan ,  COLLINO, Sebastiano ,  DUMAS, Marc-Emmanuel ,  HOLMES, Elaine ,  REZZI, Serge André Dominique ,  NICHOLSON, Jeremy ,  KOCHHAR, Sunil

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  C12Q1/61 ,  C12Q2565/633 ,  G01N24/08 ,  G01N33/50 ,  G01N33/6806 ,  G01N2800/044 ,  G01N2800/50 ,  G01N2800/60 ,  G01N2800/70

Abstract: The present invention relates generally to the field of nutrition and health. In particular, the present invention relates to a new biomarker, its use and a method that allows it to diagnose the likelihood to resist diet induced weight gain, and/or to be susceptible to a diet induced weight gain. For example, the biomarker may be isovalerylglycine.

Abstract translation: 本发明一般涉及营养和健康领域。 特别地，本发明涉及新的生物标志物，其用途和方法，其允许其诊断抵抗饮食诱导的体重增加的可能性，和/或易于饮食诱导的体重增加。 例如，生物标志物可以是异戊酰甘氨酸。

公开(公告)号：WO2013186152A1

公开(公告)日：2013-12-19

申请号：PCT/EP2013/061877

申请日：2013-06-10

Applicant: NESTEC S.A.

Inventor： MARTIN, François-Pierre ,  MONTOLIU ROURA, Ivan ,  GUY, Philippe Alexandre ,  REZZI, Serge André Dominique

IPC: G01N33/92

CPC classification number: G01N33/92 ,  G01N33/48 ,  G01N2405/04 ,  G01N2800/044

Abstract: The present invention generally relates to the field of biomarkers. In particular, the present invention relates to biomarkers such as PC-O 42: 4that can be used, for example for detecting and/or quantifying visceral adiposity and/or changes in visceral adiposity. This biomarker may also be used to diagnosing the effect of a change in lifestyle on visceral adiposity in a subject.

Abstract translation: 本发明一般涉及生物标志物领域。 特别地，本发明涉及诸如PC-O 42的生物标志物：可以用于例如检测和/或定量内脏肥胖和/或内脏肥胖的变化。 该生物标志物也可用于诊断生物体改变对受试者内脏肥胖的影响。

公开(公告)号：WO2013139584A1

公开(公告)日：2013-09-26

申请号：PCT/EP2013/054335

申请日：2013-03-05

Applicant: NESTEC S.A.

Inventor： COLLINO, Sebastiano ,  MONTOLIU ROURA, Ivan ,  MARTIN, François-Pierre ,  GUY, Philippe Alexandre ,  REZZI, Serge André Dominique

IPC: G01N33/68 ,  G01N33/92

CPC classification number: G01N33/92 ,  G01N33/50 ,  G01N33/6812 ,  G01N33/6893 ,  G01N2405/08 ,  G01N2800/7042

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using hydroxy- sphingomyelin SM-OH-22:1as biomarker.

Abstract translation: 使用基于NMR / MS的代谢组学和靶向脂质组学方法，发明人已经探索了老年人和年轻成年人的老龄化和长寿的代谢表型。 本发明人已经鉴定出降低发展与衰老有关的慢性炎症性疾病风险的生物标志物，并提出了一种诊断生活方式的方法，该方法允许使用羟基鞘磷脂SM-OH-22：1作为生物标志物来延缓和/或避免老化相关的慢性炎症性疾病。

公开(公告)号：WO2013139579A1

公开(公告)日：2013-09-26

申请号：PCT/EP2013/054325

申请日：2013-03-05

Applicant: NESTEC S.A.

Inventor： COLLINO, Sebastiano ,  MONTOLIU ROURA, Ivan ,  MARTIN, François-Pierre ,  GUY, Philippe Alexandre ,  REZZI, Serge André Dominique

IPC: G01N33/68

CPC classification number: G01N33/92 ,  A23L33/30 ,  A23V2002/00 ,  G01N33/49 ,  G01N33/6812 ,  G01N33/6848 ,  G01N33/6893 ,  G01N2405/00 ,  G01N2800/50 ,  G01N2800/7095 ,  Y10T436/182 ,  Y10T436/24

Abstract: Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors haveexploredthe metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using 9-oxo-HODE as biomarker.

Abstract translation: 使用基于NMR / MS的代谢组学和靶向脂质组学方法，发明人已经研究了老年人和年轻成年人的老龄化和长寿的代谢表型。 本发明人已经鉴定出降低发展与衰老有关的慢性炎症性疾病的风险的生物标志物，并且提出了一种诊断生活方式的方法，该方法允许使用9-氧代-HODE作为生物标志物延迟和/或避免老化相关的慢性炎症性疾病。

公开(公告)号：WO2010003803A1

公开(公告)日：2010-01-14

申请号：PCT/EP2009/057656

申请日：2009-06-19

Applicant: NESTEC S.A. ,  FICHOT, Marie-Claire ,  SPRENGER, Norbert ,  MARTIN, François-Pierre ,  KOCHHAR, Sunil ,  REZZI, Serge

Inventor： FICHOT, Marie-Claire ,  SPRENGER, Norbert ,  MARTIN, François-Pierre ,  KOCHHAR, Sunil ,  REZZI, Serge

IPC: A23L1/29 ,  A23L1/30 ,  A23L1/308 ,  A23L2/52 ,  A23L1/09 ,  A61K31/702 ,  A61P43/00

CPC classification number: A23L1/296 ,  A23L2/52 ,  A23L5/00 ,  A23L29/30 ,  A23L33/10 ,  A23L33/125 ,  A23L33/135 ,  A23L33/22 ,  A23L33/40 ,  A23V2002/00 ,  A61K35/744 ,  A61K35/745 ,  A61K35/747 ,  A61K45/06 ,  A23V2250/28 ,  A23V2250/704 ,  A23V2250/70 ,  A23V2250/156 ,  A23V2200/332

Abstract: A nutritional composition for administration to an infant which composition comprises, on a dry matter basis, from 2.5 to 15.0 wt% of an oligosaccharide mixture consisting of N-acetylated oligosaccharide(s), galacto-oligosaccharide(s) and sialylated oligosaccharide(s) with the proviso that the composition comprises at least 0.02 wt% of an N-acetylated oligosaccharide, at least 2.0 wt% of a galacto-oligosaccharide and at least 0.04 wt% of a sialylated oligosaccharide and that the N-acetylated oligosaccharide(s) comprise 0.5 to 4.0% of the oligosaccharide mixture, the galacto- oligosaccharide(s) comprise 92.0 to 98.5% of the oligosaccharide mixture and the sialylated oligosaccharide(s) comprise 1.0 to 4.0% of the oligosaccharide mixture. The composition is useful for administration to an infant in the first six months of life to reduce the risk of obesity later in life.

Abstract translation: 一种用于给予婴儿的营养组合物，其中所述组合物以干物质为基础，包含2.5至15.0重量％的由N-乙酰化寡糖，低聚半乳糖和唾液酸化寡糖组成的寡糖混合物， 条件是组合物包含至少0.02重量％的N-乙酰化寡糖，至少2.0重量％的低聚半乳糖和至少0.04重量％的唾液酸化寡糖，并且N-乙酰化寡糖包含 0.5至4.0％的寡糖混合物，寡聚半乳糖包含92.0至98.5％的寡糖混合物，唾液酸化寡糖包含1.0至4.0％的寡糖混合物。 该组合物可用于在生命的头六个月给予婴儿以降低生命后期的肥胖风险。

公开(公告)号：WO2016116584A1

公开(公告)日：2016-07-28

申请号：PCT/EP2016/051286

申请日：2016-01-22

Applicant: NESTEC S.A.

Inventor： SCHIFFRIN, Eduardo ,  BRAHMBHATT, Viral ,  MARTIN, François-Pierre ,  MONTOLIU ROURA, Ivan ,  REZZI, Serge André Dominique ,  BENYACOUB, Jalil

IPC: G01N33/68

CPC classification number: G01N33/92 ,  G01N33/53 ,  G01N33/6893 ,  G01N2405/04 ,  G01N2405/08 ,  G01N2800/065 ,  G01N2800/54

Abstract: The invention relates to a method, a system and kit for identifying the sample of a patient having IBD or predicting the relapse of IBD in patients based on the measurement of biomarkers in a sample of the patient. The biomarkers can be lipids or amino acids or a combination thereof.

Abstract translation: 本发明涉及一种方法，系统和试剂盒，用于基于患者样品中生物标志物的测量来鉴定患有IBD的患者样本或预测患者IBD复发的样本。 生物标志物可以是脂质或氨基酸或其组合。

公开(公告)号：WO2015104113A1

公开(公告)日：2015-07-16

申请号：PCT/EP2014/077038

申请日：2014-12-09

Applicant: NESTEC S.A.

Inventor： BEGUELIN, Fiona Camille ,  COLLINO, Sebastiano ,  MARTIN, François-Pierre ,  MONTOLIU ROURA, Ivan ,  SCHERER, Max

IPC: G01N33/92

CPC classification number: G01N33/92 ,  A23L33/30 ,  A23V2002/00 ,  G01N2405/00 ,  G01N2405/04 ,  G01N2570/00 ,  G01N2800/324 ,  G01N2800/50 ,  G09B19/00 ,  G09B19/0092

Abstract: A method for predicting the level of epicardial adipose tissue (EAT) in a subject comprising: (a) determining a level of one or more lipid biomarkers in a sample from the subject, wherein the biomarkers are selected from the following: (i) phosphatidylcholine (PC) [16:1/16:1] (ii) diacylglycerol (DAG) [42:8] (iii) phosphatidylethanolamine-ether(PE-O) [32:5] (iv) phosphatidylcholine(PC) [18:0 / 22:5] (v)phosphatidylinositol (PI) [18:0 / 16:1] (vi)phosphatidylglycerol (PG) [20:3 / 20:3] (vii) phosphatidylglycerol (PG) [22:5 / 18:1] (b) comparing the levels of the biomarkers in the sample to reference values; wherein the levels of the biomarkers in the sample compared to the reference values are indicative of levels of EAT fat in the subject.

Abstract translation: 一种用于预测受试者的心外膜脂肪组织（EAT）水平的方法，包括：（a）测定来自受试者的样品中一种或多种脂质生物标志物的水平，其中所述生物标志物选自以下：（i）磷脂酰胆碱 （PC）[16：1/16：1]（ii）二酰基甘油（DAG）[42:8]（iii）磷脂酰乙醇胺 - 醚（PE-O）[32：5]（iv）磷脂酰胆碱（PC） （v）磷脂酰肌醇（PI）[18：0/16：1]（vi）磷脂酰甘油（PG）[20：3/20：3]（vii）磷脂酰甘油（PG）[22： 18：1]（b）将样品中生物标志物的水平与参考值进行比较; 其中与参考值相比，样品中生物标志物的水平指示受试者中EAT脂肪的水平。